The expression level of PD-L1 in tumor tissues of various cancer patients is considered the main predictive biomarker for the identification of patients who are likely to receive therapeutic benefit from anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and cancer.